ECP
ARLZ

Elk Creek Partners’s Aralez Pharmaceuticals Inc. ARLZ Stock Holding History

Elk Creek Partners’s Portfolio ARLZ Stock Details ARLZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-2,488,475
Closed -$5.33M – 166
2017
Q1 		$5.33M Buy
2,488,475
+292,420
+13% +$1.1M 0.33% 103
2016
Q4 		$9.69M Buy
2,196,055
+55,004
+3% +$261K 0.65% 61
2016
Q3 		$10.4M Buy
2,141,051
+626,133
+41% +$2.86M 0.68% 59
2016
Q2 		$5M Buy
1,514,918
+122,172
+9% +$461K 0.36% 100
2016
Q1 		$4.94M Buy
+1,392,746
New +$7.18M 0.37% 98

Other funds holding ARLZ

PCM
PAR Capital Management Boston, Massachusetts $4.03B AUM 35.05% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return

Elk Creek Partners's ARLZ Position: Q2 2017 in Review

Elk Creek Partners sold out of Aralez Pharmaceuticals Inc. (ARLZ) in Q2 2017, closing a stake of 2,488,475 shares — an estimated $5.33M sold.

Elk Creek Partners first reported a position in ARLZ in Q1 2016 and held it in 5 quarters. The position peaked at $10.4M in Q3 2016. 72 funds tracked by Wall St. Rank hold ARLZ as of Q2 2017.

  • Elk Creek Partners reported no remaining Aralez Pharmaceuticals Inc. position as of Q2 2017 after selling out during the quarter.
  • Elk Creek Partners sold 2,488,475 Aralez Pharmaceuticals Inc. shares in Q2 2017, an estimated $5.33M.
  • Elk Creek Partners first reported a position in Aralez Pharmaceuticals Inc. in Q1 2016 and held it in 5 quarters.
  • Elk Creek Partners's Aralez Pharmaceuticals Inc. position peaked at $10.4M in Q3 2016.
  • 72 funds tracked by Wall St. Rank held Aralez Pharmaceuticals Inc. as of Q2 2017.

Based on Elk Creek Partners's 13F filing for Q2 2017, filed 11 Aug 2017.